论文部分内容阅读
目的:观察小剂量米非司酮治疗子宫肌瘤的临床治疗效果。方法:选取2011年12月~2013年12月间接收的110例子宫肌瘤患者作为观察对象,随机分为观察组和对照组各55例。观察组患者服用小剂量米司非酮治疗,每天剂量为12.5 mg,对照组患者服用米非司酮的剂量为每天25 mg,两组患者均服药3个月。结果:观察组患者的子宫体积和子宫肌瘤体积明显变小,血红蛋白水平也出现了明显的上升,和治疗前比较有差异,P<0.05,和对照组比较无统计学意义,P>0.05。观察组患者中有4例患者有恶心呕吐的不良反应,对照组中有5例患者有恶心呕吐,13例患者有潮热出现,观察组的不良反应明显比对照组少,比较有差异,P<0.05。结论:对子宫肌瘤患者给予小剂量米司非酮进行治疗,临床效果较为显著,安全可靠,值得应用和推广。
Objective: To observe the clinical efficacy of low-dose mifepristone in the treatment of uterine fibroids. Methods: A total of 110 cases of uterine leiomyoma received from December 2011 to December 2013 were selected as observation subjects and randomly divided into observation group and control group with 55 cases each. Patients in the observation group took a small dose of mifepristone at a daily dose of 12.5 mg. Patients in the control group took mifepristone at a dose of 25 mg daily for 3 months. Results: The volume of uterine fibroids and the volume of uterine fibroids in observation group decreased significantly, and hemoglobin level also increased obviously. There was a significant difference between before and after treatment (P <0.05). There was no significant difference between the two groups (P> 0.05). In the observation group, 4 patients had adverse reactions of nausea and vomiting, 5 patients in the control group had nausea and vomiting, 13 patients had hot flashes, and adverse reactions in the observation group were significantly less than those in the control group, P <0.05. Conclusion: The treatment of uterine fibroids with low-dose mifepristone is more effective and safe, which is worthy of application and promotion.